Vistagen Therapeutics, Inc. (VTGN)
XMEX 
NASDAQ (CM) Primary XMEX Summary
VTGN Chart
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.
Vistagen Therapeutics, Inc. (VTGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vistagen Therapeutics, Inc. ever had a stock split?
Vistagen Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Shawn K. Singh CEO | XMEX Exchange | US92840H4002 ISIN |
| US Country | 41 Employees | - Last Dividend | 7 Jun 2023 Last Split | 6 May 2016 IPO Date |
Overview
VistaGen Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical entity committed to the innovation and commercialization of novel treatments designed predominantly for disorders affecting the central nervous system (CNS), such as anxiety and depression. With its establishment in 1998 and headquartered in South San Francisco, California, VistaGen has dedicated its efforts towards developing medicines that promise to transform the treatment landscape for patients grappling with CNS disorders. Its collaborations and agreements with notable organizations like Cato Research Ltd., Pherin Pharmaceuticals, Inc., and EverInsight Therapeutics Inc. underline its strategic approach to advancing its product pipeline through critical development phases towards market readiness.
Products and Services
- PH94B
- PH10
- AV-101
This innovative neuroactive nasal spray is charting a path through Phase III development, specifically targeting the acute treatment of anxiety among adults suffering from social anxiety disorder. PH94B stands out for its rapid-onset action, setting a new precedent in anxiety disorder treatment efficacy and convenience. Beyond social anxiety disorder, PH94B harbors the potential to significantly impact the treatment of a broad spectrum of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), preprocedural anxiety, and panic disorders.
Another promising candidate in VistaGen's CNS pipeline, PH10 mirrors the rapid-onset characteristic of PH94B but is directed towards a different therapeutic goal. Presently gearing up for Phase 2B clinical development, PH10 is poised to emerge as a groundbreaking stand-alone treatment for major depressive disorder (MDD). Its development underscores VistaGen's commitment to addressing the unmet needs in the treatment of depression with novel and efficacious solutions.
Expanding the diversity of VistaGen's pipeline, AV-101 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist undergoing development for multiple potential applications. Among these, the combination of AV-101 with oral probenecid represents a novel approach to the treatment of levodopa-induced dyskinesia, a common complication in the management of Parkinson's disease. Furthermore, AV-101's development trajectory includes potential applications in treating MDD, neuropathic pain, and suicidal ideation, showcasing the compound's versatility and VistaGen's broad therapeutic ambitions within the CNS domain.
